The most prevalent malignancy in women, affects more than 2 million individuals each year
# Treatment
* Dependant on:
	* Receptor status
	* Gene Expression Signature
		* PAM50:
			* 50-gene signature measures allows for the classification into four/five biologically distinct intrinsic subtypes while simultaneously generating data to determine the prognostic ROR score. Able to differentiate:
				* Incidence
				* Progression
				* Treatment Response
* A significant proportion of patients either do not respond to the therapies or develop resistance and therefore relapse